RecruitingNot ApplicableNCT07477236

MyVitalC: Sleep and Everyday Headache Management

A Real-World, Single-Arm Observational Study Evaluating the Effects of MyVitalC (ESS60 in Extra Virgin Olive Oil) on Sleep Disturbance and Everyday Headaches

Sponsor

Efforia, Inc

Enrollment

100 participants

Start Date

Jan 24, 2026

Study Type

INTERVENTIONAL

Conditions

Sleep

Summary

Sleep disturbance and recurring headaches can negatively affect daily functioning, mood, and productivity. MyVitalC (ESS60 in extra virgin olive oil) is a commercially available dietary supplement that has generated anecdotal claims related to sleep quality and headache relief; however, human data remain limited. This real-world observational study is designed to help participants evaluate whether use of MyVitalC is associated with changes in sleep disturbance and headache frequency or severity in their own daily lives. Participants will complete a four-week baseline observation period without the intervention, followed by six weeks of daily MyVitalC use, with weekly self-reported assessments. Participants serve as their own control, allowing for within-person comparison of outcomes before and during product use.

Eligibility

Inclusion Criteria4

Adults of legal age of consent
Able to provide informed consent
Willing to complete weekly assessments and daily logs
Able to purchase and use the study product

Exclusion Criteria7

Have known allergies to olive oil or product components
Are pregnant or breastfeeding
Have severe or chronic headache disorders
Have significant gastrointestinal conditions
Have medical conditions that could be exacerbated by supplement use
Have concerns about dizziness, fatigue, or mood disturbances
Are subject to organizational or legal restrictions on supplement use

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTMyVitalC (ESS60 in Extra Virgin Olive Oil)

Participants will take 1 teaspoon (5 mL) of MyVitalC, ESS60 in extra virgin olive oil, orally once daily in the morning, with or without food, for six weeks. Daily intake is logged within the study platform.